R R

What Is Qinlock?

Qinlock is a prescription targeted cancer medication containing ripretinib, a kinase inhibitor. It is approved to treat adults with advanced gastrointestinal stromal tumors (GIST) who have previously received at least three kinase inhibitors, including imatinib. GIST is a type of tumor that commonly develops in the digestive tract and may involve abnormal signaling through certain growth-related proteins. Qinlock is taken orally once daily. It helps interfere with signaling involved in tumor growth but does not cure advanced GIST. Treatment requires oncology supervision and monitoring for adverse reactions.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Qinlock?

Qinlock is a prescription targeted cancer medication containing ripretinib, a kinase inhibitor. It is approved to treat adults with advanced gastrointestinal stromal tumors (GIST) who have previously received at least three kinase inhibitors, including imatinib. GIST is a type of tumor that commonly develops in the digestive tract and may involve abnormal signaling through certain growth-related proteins. Qinlock is taken orally once daily. It helps interfere with signaling involved in tumor growth but does not cure advanced GIST. Treatment requires oncology supervision and monitoring for adverse reactions.

read more about qinlock ...

Copy this HTML:

Copy HTML Copied!

How Does Qinlock Work?

Qinlock contains ripretinib, a switch-control kinase inhibitor that targets signaling involving KIT and platelet-derived growth factor receptor alpha, or PDGFRA. Alterations in these proteins can contribute to the growth and survival of gastrointestinal stromal tumor cells. Ripretinib stabilizes certain inactive forms of the targeted kinases, reducing their signaling activity. This can slow tumor growth in susceptible cancers, including some tumors with resistance mutations that developed during earlier treatment. Qinlock also affects other kinases, which can contribute to adverse effects. Its clinical benefit depends on the cancer's characteristics and previous treatments.

Who Can Receive Qinlock Treatment?

Qinlock is approved for adults with advanced gastrointestinal stromal tumors who have received prior treatment with three or more kinase inhibitors, including imatinib. It is generally used after disease progression or intolerance to previous targeted treatments. An oncologist reviews the diagnosis, treatment history, disease status, cardiovascular health, and other medications before prescribing Qinlock. It is not approved as first-line treatment for GIST or for every cancer involving abnormal kinase activity. Patients require monitoring for skin changes, blood pressure, cardiac function, and treatment-related complications.

How Should Qinlock Be Taken?

The recommended Qinlock dose is 150 mg orally once daily, with or without food. The dose consists of three 50 mg tablets, which should be swallowed whole and taken at approximately the same time each day. If fewer than eight hours have passed since a missed dose, patients may take it; otherwise, they should skip the missed dose and resume the regular schedule. Do not repeat a dose after vomiting. Treatment continues until disease progression or unacceptable toxicity. Dose interruption or reduction may be required for certain adverse effects, and strong CYP3A inhibitors or inducers may require special management.

What Are the Side Effects and Warnings of Qinlock?

Common adverse effects include hair loss, fatigue, nausea, abdominal pain, constipation, muscle pain, and hand-foot skin reactions. Serious risks include high blood pressure, cardiac dysfunction, new primary skin cancers, and impaired wound healing. Palmar-plantar erythrodysesthesia can cause painful redness, swelling, or peeling on the hands and feet. Qinlock can also harm an unborn baby. Clinicians monitor blood pressure, assess skin changes, and evaluate heart function when appropriate. Patients should report chest pain, shortness of breath, severe skin reactions, or unusual lesions. Treatment may need to be withheld before planned surgery.

Common Questions About Qinlock

Is Qinlock the same as ripretinib?

Yes. Qinlock is the brand name for ripretinib, a targeted kinase inhibitor used for certain advanced gastrointestinal stromal tumors.

What type of cancer does Qinlock treat?

Qinlock treats advanced gastrointestinal stromal tumors in adults who have received at least three previous kinase inhibitors, including imatinib.

How often is Qinlock taken?

Qinlock is generally taken once daily at a dose of 150 mg, equivalent to three 50 mg tablets.

Can Qinlock cause skin problems?

Yes. Qinlock can cause painful hand-foot skin reactions and increase the risk of certain new skin cancers. Regular skin examinations are recommended.

References

DailyMed - QINLOCK (ripretinib) tablet. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9f18e462-03dd-4296-a02a-a0577e3ee78d. Date Accessed November 2, 2026.

Qinlock. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/qinlock. Date Accessed November 2, 2026.

Ripretinib. MedlinePlus. https://medlineplus.gov/druginfo/meds/a620035.html. Date Accessed November 2, 2026.

Ripretinib in Patients With Advanced Gastrointestinal Stromal Tumours (INVICTUS): A Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial. The Lancet Oncology. https://pubmed.ncbi.nlm.nih.gov/32511981/. Date Accessed November 2, 2026.

Ripretinib. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Ripretinib. Date Accessed November 2, 2026.